Authors did not respond to a request for the data.Small low-risk patient RCT with 30 low-dose ivermectin and 26 control patients, with no primary outcome events in either arm. Viral load was significantly better with ivermectin on day 5, while there was no significant difference on day 1 or day 14. There was no significant difference in combined symptoms, however authors include cough which was the most frequent symptom and may persist long after infection has been cleared. Ivermectin patients were 4 years older with a higher standard deviation, had higher prevalence of obesity, diabetes, hypertension, and cardiovascular disease, and lower prevalence of hepatic and kidney disease.External influences may have altered the paper. For example, authors state: "Taken together, these data do not show that ivermectin is effective in the treatment of COVID-19 by "accelerating" viral clearance in the first week, which may translate into a lower rate of complications." Elsewhere, authors note faster viral clearance at day 5, which is usually considered to be a positive result. This sentence may have been modified to be negative, while not fully updating the new sentence to be logical.Authors report 45.8% asymptomatic placebo patients on day 14, howevere there is no number of 26 patients that is 45.8%. Authors report 18% of ivermectin patients asymptomatic at day 5, however there is no number of 30 patients that is 18%.